Lamivudine/tenofovir disoproxil and Alcohol/Food Interactions
There are 2 alcohol/food/lifestyle interactions with lamivudine / tenofovir disoproxil.
Tenofovir Food
Minor Food Interaction
Information for this minor interaction is available on the professional version.
Lamivudine High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)
Major Potential Hazard, Moderate plausibility
NRTIs - pancreatitis
The nucleoside reverse transcriptase inhibitors, didanosine, stavudine, and lamivudine, may cause pancreatitis. The incidence is generally low but is up to 7% with didanosine, and up to 18% in pediatric patients given lamivudine. Patients with a history of or known risk factors for pancreatitis (such as alcohol abuse or hypertriglyceridemia) should be monitored closely during therapy with these agents. Therapy should be discontinued at the first signs/symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.
Lamivudine/tenofovir disoproxil drug interactions
There are 241 drug interactions with lamivudine / tenofovir disoproxil.
Lamivudine/tenofovir disoproxil disease interactions
There are 7 disease interactions with lamivudine / tenofovir disoproxil which include:
- hepatitis B
- hepatotoxicity
- pancreatitis
- renal dysfunction
- bone toxicity
- liver disease
- renal dysfunction
More about lamivudine / tenofovir disoproxil
- lamivudine/tenofovir disoproxil consumer information
- Check interactions
- Compare alternatives
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- Drug class: antiviral combinations
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.